Catalyst Dossier · compiled by Celia 🧫

Johnson & Johnson (JNJ)

Pharmaceutical Preparations · market cap $549.8B · as of 2026-06-23

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-15

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Johnson & Johnson is a diversified multinational pharmaceutical and medical technology company with a $550B market cap, operating two segments: Innovative Medicine (64% of 2025 revenues) and MedTech (36%). Key marketed products include DARZALEX (15.2% of revenues) and CARVYKTI in oncology/hematology, with upcoming catalysts centered on Phase 3 nipocalimab (May 2027, high importance) and Phase 2 amivantamab IV (April 2027). Despite its scale, the FACTS flag several pipeline entries that appear to be legacy or off-label trials for already-genericized molecules, raising questions about the clinical registry data underlying the 'lead asset' designation.

The catalyst path

2026-07-15Earningsimp 5/10
2027-04-27 (est.)Phase 2 · Amivantamab IVimp 7/10
2027-05-14 (est.)Phase 3 · Nipocalimabimp 9/10

Pipeline

Asset	Phase	Indication
galantamine ER	Phase 3	Alzheimer's Disease
R228060	Phase 2	Major Depressive Disorder
Test acetaminophen	Phase 3	Post-operative Dental Pain
risperidone oral tablets	Phase 3	Anxiety Disorders
Doxorubicin	Phase 3	Sarcoma
CG 5503;tapentadol	Phase 3	Osteoarthritis
tapentadol (CG5503) ER	Phase 3	Low Back Pain
JNJ-90301900	Phase 2	Carcinoma, Non-Small-Cell Lung
Experimental Product 1% Colloidal Oatmeal Balm	Phase 2	Atopic Dermatitis
levofloxacin	Phase 3	Pneumonia
JNJ16269110	Phase 2	Diabetes Mellitus, Type 2
Rivaroxaban	Phase 3	Atrial Fibrillation
ibuprofen; pseudoephedrine HCl	Phase 2	Enuresis
tapentadol (CG5503) Immediate Release IR	Phase 3	Low Back Pain
levofloxacin, azithromycin, amoxicillin/clavulanate	Phase 3	Bronchitis
Acetaminophen/Naproxen Sodium Fixed Combination	Phase 3	Pain
Bortezomib	Phase 3	Multiple Myeloma
Paliperidone extended-release	Phase 3	Bipolar Disorder
Risperdal Consta	Phase 3	Bipolar Disorder
Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)	Phase 3	Multiple Myeloma

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by Celia. The catalyst path & pipeline above are free.

See Pro

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by Celia. Not financial advice.